Back to top

Analyst Blog

Synergy Pharmaceuticals Inc. (SGYP - Snapshot Report) recently announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the clinical development plan for its pipeline candidate plecanatide.

We note that Synergy Pharma is developing plecanatide for the treatment of patients suffering from chronic idiopathic constipation (CIC).

As per the agreement with the FDA, Synergy Pharma will initiate a phase III study by year end to evaluate the safety and efficacy of plecanatide in CIC patients.

The FDA has also agreed on the design, duration, size and primary and secondary efficacy endpoints of the phase III studies.

We are encouraged by the pipeline progress at Synergy Pharma. In May 2013, Synergy Pharma reported positive results from a multicenter trial on plecanatide for the CIC indication.

Synergy Pharma observed statistically significant improvement in the number of complete spontaneous bowel movements among patients, who were administered three doses of plecanatide.

We remind investors that Synergy Pharma is also developing plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C). The company initiated the first trial in IBS-C patients in late 2012.

Currently, a phase IIb trial evaluating plecanatide in IBS-C patients is underway and Synergy Pharma expects to release top-line data from this trial in the first quarter of 2014.

We expect investor focus to remain on updates regarding the development of plecanatide. The successful development and commercialization of plecanatide would be a major positive for Synergy Pharma, which currently has no approved drug.

However, plecanatide is expected to face stiff competition on approval. The constipation market already includes Ironwood Pharmaceuticals/ Forest Laboratories’ (IRWD - Analyst Report)/ Linzess.

Synergy Pharma currently carries a Zacks Rank #3 (Hold). Right now, Shire (SHPG - Analyst Report) looks attractive with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.45 +5.45%
BITAUTO HOL… BITA 81.94 +5.42%
CTPARTNERS… CTP 16.49 +3.19%
CHINA BIOLO… CBPO 47.80 +3.06%
US SILICA H… SLCA 64.69 +3.04%